Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 3/20 | 0.62 |
| ▸ | AR | P10275 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | HSD3B1 | P14060 | 1/20 | 0.47 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217723 | 1.00 | SRD5A2 (0.62) | SRD5A2ARKCNH2LMNACYP3A4 | |
| SCHEMBL20368986 | 0.87 | SRD5A2 (0.62) | SRD5A2ARLMNACYP3A4CYP2C9 | |
| SCHEMBL5247468 | 0.86 | AR (0.58) | SRD5A2ARKCNH2 | |
| SCHEMBL5339929 | 0.86 | AR (0.58) | SRD5A2ARKCNH2 | |
| SCHEMBL5242813 | 0.86 | AR (0.55) | SRD5A2ARKCNH2 | |
| SCHEMBL5341211 | 0.86 | AR (0.55) | SRD5A2ARKCNH2 | |
| SCHEMBL5215956 | 0.85 | SRD5A1 (0.64) | SRD5A2ARSRD5A1 | |
| SCHEMBL7079738 | 0.85 | SRD5A1 (0.64) | SRD5A2ARSRD5A1 | |
| SCHEMBL5218071 | 0.83 | AR (0.58) | SRD5A2ARSRD5A1 | |
| SCHEMBL7077337 | 0.83 | AR (0.58) | SRD5A2ARSRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6645974-B2 | Administering an androstamide compound; osteoporosis, anticancer agents, glandular disorders | MERCK & CO., INC. | 2003-11-11 | — | — | US | claimed |
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | claimed |
| US-6645974-B2 | Administering an androstamide compound; osteoporosis, anticancer agents, glandular disorders | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | AR, FSHR, SHBG | SRD5A2 80/4885AR 1/4885KCNH2 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.